Previous 10 | Next 10 |
CARSON CITY, Nev., May 16, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease,&...
BioVie Inc. (NASDAQ: BIVI) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.49% on the day to $8.2. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its prod...
BioVie Inc. (NASDAQ: BIVI) is the focus of IBN's latest stock spotlight. The company's shares have moved -7.09% on the day to $7.21. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its pr...
CARSON CITY, Nev., April 20, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...
BioVie Inc. (NASDAQ: BIVI) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.98% on the day to $8.25. BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its pro...
CARSON CITY, Nev., April 17, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...
2023-04-10 06:00:47 ET Summary Seven months separate BioVie investors from Phase 3 results in Alzheimer’s disease. During BioVie Day, the company announced six upcoming Phase 3 trials in Alzheimer’s, Parkinson’s, MCI and ascites. Good Phase 2 results in Pa...
ORLANDO, FL / ACCESSWIRE / March 24, 2023 / RedChip Companies will air new interviews with BioVie Inc. (NASDAQ:BIVI) and iRemedy on The RedChip Money Report® on Bloomberg TV, this Saturday, March 25, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes acr...
CARSON CITY, Nev., March 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...
--News Direct-- BioVie CEO Cuong Do joins Proactive's Natalie Stoberman to share the details of the company's upcoming BioVie Day webinar on March 23. Do says BioVie Day will feature a comprehensive overview of the company’s programs in Alzheimer’s disease, Parkinson’...
News, Short Squeeze, Breakout and More Instantly...
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Ti...
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to carbidopa/levodopa Additional presentation at congress highlighted data from earlier Phase 2a trial of bezisterim in Parkinson...
ORLANDO, FL / ACCESSWIRE / June 21, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Mobilicom Ltd. (Nasdaq:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 22, at 7 p.m. Eastern Time (ET). Bloomb...